FDA clears C2N Diagnostics' PrecivityAD2 blood test for Alzheimer's diagnosis in adults aged 40+

The US FDA has cleared C2N Diagnostics' PrecivityAD2 blood test for diagnosing Alzheimer's disease in adults aged 40 and older with cognitive symptoms, marking the first FDA-cleared diagnostic for this age group. The test uses high-resolution mass spectrometry to measure amyloid and tau proteins, showing high predictive values in clinical trials, and is expected to become available later this year.

This Wire brief sits within Fusion42's coverage of Digital Health, and 3 sources have reported it.